PPLPHARMA
Piramal Pharma Limited (PPLPHARMA) Stock Analysis
Piramal Pharma Limited develops and manufactures inhalation anaesthetics, complex hospital generics, and contract development services. It serves global pharma and hospital customers from Indian and UK facilities. The company was demerged from the Piramal group pharma operations. It is listed on Indian stock exchanges.
Healthcare › Drug Manufacturers - Specialty & Generic
₹196.90
-0.55% 1W | -2.60% 52W
Market Cap
26.1k CR
P/E Ratio
–
52W High
₹231.9
52W Low
₹132.3
Div. Yield
0%
Beta
0.3
50 DMA
₹209.1
200 DMA
₹174.2
Profit Margin
-3.4%
Inst. Own.
19.9%
✅ BOUNCE FROM SUPPORT
✅ BOUNCE FROM SUPPORT
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,749 | 1,911 | 1,959 | 2,552 | 1,951 | 2,242 | 2,204 | 2,754 | 1,934 | 2,044 | 2,140 | 2,752 | 2,270 |
| Expenses | 1,617 | 1,646 | 1,690 | 2,022 | 1,747 | 1,900 | 1,866 | 2,193 | 1,827 | 1,885 | 1,944 | 2,291 | 2,075 |
| Operating Profit | 132 | 266 | 268 | 530 | 204 | 342 | 338 | 561 | 107 | 159 | 196 | 461 | 195 |
| OPM % | 8% | 14% | 14% | 21% | 10% | 15% | 15% | 20% | 6% | 8% | 9% | 17% | 9% |
| Other Income | 53 | 68 | 43 | 8 | 42 | 78 | 29 | 58 | 98 | 80 | 12 | -116 | 109 |
| Interest | 119 | 110 | 106 | 114 | 107 | 108 | 103 | 104 | 86 | 82 | 89 | 83 | 88 |
| Depreciation | 174 | 185 | 186 | 196 | 185 | 192 | 197 | 243 | 197 | 203 | 213 | 218 | 224 |
| Profit before tax | -107 | 40 | 19 | 227 | -45 | 120 | 67 | 273 | -79 | -46 | -94 | 43 | -7 |
| Tax % | -8% | 87% | 48% | 55% | 97% | 81% | 94% | 44% | 3% | 115% | 45% | 121% | 830% |
| Net Profit | -99 | 5 | 10 | 101 | -89 | 23 | 4 | 154 | -82 | -99 | -136 | -9 | -69 |
| EPS in Rs | -0.75 | 0.04 | 0.08 | 0.77 | -0.67 | 0.17 | 0.03 | 1.16 | -0.61 | -0.75 | -1.02 | -0.07 | -0.52 |
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 6,315 | 6,559 | 7,082 | 8,171 | 9,151 | 8,869 | 9,205 |
| Expenses | 4,887 | 5,609 | 6,453 | 6,974 | 7,706 | 7,947 | 8,195 |
| Operating Profit | 1,428 | 950 | 629 | 1,197 | 1,445 | 922 | 1,010 |
| OPM % | 23% | 14% | 9% | 15% | 16% | 10% | 11% |
| Other Income | 230 | 319 | 272 | 172 | 208 | 74 | 86 |
| Interest | 163 | 198 | 344 | 448 | 422 | 341 | 343 |
| Depreciation | 545 | 586 | 677 | 741 | 816 | 831 | 858 |
| Profit before tax | 949 | 485 | -120 | 179 | 415 | -176 | -104 |
| Tax % | 12% | 22% | 55% | 90% | 78% | 85% | |
| Net Profit | 835 | 376 | -186 | 18 | 91 | -326 | -314 |
| EPS in Rs | -1.41 | 0.13 | 0.69 | -2.45 | -2.36 | ||
| Dividend Payout % | 0% | 18% | 0% | 82% | 20% | 0% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 8.0% | 7.0% | – |
| Profit CAGR | -31.0% | – | – |
Shareholding Pattern
Promoters34.85%
FIIs30.86%
DIIs14.25%
Public19.46%
Promoters34.85%
FIIs30.27%
DIIs14.89%
Public19.46%
Promoters34.85%
FIIs29.66%
DIIs15.68%
Public19.35%
Promoters34.85%
FIIs30.17%
DIIs15.61%
Public19.01%
Promoters34.80%
FIIs12.51%
DIIs14.57%
Public37.62%
Promoters34.78%
FIIs39.28%
DIIs4.98%
Public20.57%
Promoters35.02%
FIIs30.58%
DIIs12.12%
Public21.89%
Promoters34.94%
FIIs31.49%
DIIs14.78%
Public18.42%
Promoters34.85%
FIIs30.17%
DIIs15.61%
Public19.01%
Promoters34.80%
FIIs12.51%
DIIs14.57%
Public37.62%
PPLPHARMA
Holdings Analysis
Key strengths & risk signals
57
Overall
37
Fundamental
77
Technical
Risks (4)
Cannot calculate PEG - insufficient growth data.
RECOVERY MODE! Current price (196.9) above 200-day but below 50-day.
WEAK YEAR! Stock declined 2.6% in the last year.
WEAK MOMENTUM! Limited price growth - -0.6% (1 week), -9.7% (1 month), 11.1% (3 months).
Strengths (3)
BULLISH TREND! 50-day average (209.1) is above 200-day average (174.2) - positive signal.
BULLISH SENTIMENT! In last 30 days: 15 up days, 15 down days. Avg volume on up days: 4,640,189 vs down days: 2,910,243. Ratio: 1.59x
LOW VOLATILITY! Beta of 0.30 - stable stock, less market risk.
Fundamental & Technical Analysis
57Overall
37Fundamental
77Technical
Fundamental Breakdown
Growth Quality
10/30
Revenue CAGR: 7.6% (MODERATE, 8/15). Profit CAGR: 0% (DECLINING, 2/15).
Profit Margin
2/10
LOW MARGIN! -3.4% profit margin - thin profits.
PEG Valuation
0/10
Cannot calculate PEG - insufficient growth data.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0% yield - little to no income.
Debt to Equity
6/10
MODERATE DEBT! D/E of 0.60 - acceptable leverage.
Public Holding
14/20
MODERATE PUBLIC HOLDING! 24.32% public ownership - balanced ownership structure.
Stability Index
2/10
CAUTION! Company made loss in last quarter. Be careful.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (209.1) is above 200-day average (174.2) - positive signal.
Price Position
2/10
RECOVERY MODE! Current price (196.9) above 200-day but below 50-day.
Trend Pattern
16/20
TESTING SUPPORT! Stock is at key support level.
52W Performance
3/10
WEAK YEAR! Stock declined 2.6% in the last year.
Volume Sentiment
30/30
BULLISH SENTIMENT! In last 30 days: 15 up days, 15 down days. Avg volume on up days: 4,640,189 vs down days: 2,910,243. Ratio: 1.59x
RSI
3/5
NEUTRAL! RSI at 41.7 - balanced momentum.
52W Range
4/5
UPPER HALF! Trading at 64.9% of 52W range - positive territory.
Momentum
2/5
WEAK MOMENTUM! Limited price growth - -0.6% (1 week), -9.7% (1 month), 11.1% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.30 - stable stock, less market risk.
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PPLPHARMA | ₹196.90 | – | -3.4% | 7.6% | – | -2.6% | 57 | BOUNCE FROM SUPPORT | -15.1% | +688.6% | +17.4% | -17.5% |
| NEULANDLAB | ₹20,890.00 | 53.8 | 21.0% | 18.5% | 30.6% | +28.8% | 73 | BREAKDOWN | +962.6% | -30.6% | +119.1% | -17.4% |
| GRANULES | ₹815.20 | 30.3 | 11.8% | 5.9% | 4.8% | +48.7% | 64 | CONSOLIDATION | +59.9% | -10.7% | +21.2% | +0.5% |
| WOCKPHARMA | ₹1,996.40 | 79.3 | 11.2% | 7.8% | – | +43.1% | 58 | CONSOLIDATION | -217.8% | -36.1% | +25.9% | -3.7% |
| EMCURE | ₹1,833.50 | 34.4 | 10.4% | 15.4% | 20.2% | +34.8% | 81 | BREAKDOWN | +42.0% | +20.8% | +22.8% | +4.5% |
| AJANTPHARM | ₹3,410.10 | 37.6 | 19.6% | 13.4% | 21.6% | +41.1% | 76 | BREAKDOWN | +30.9% | +25.3% | +24.8% | +14.4% |
| IPCALAB | ₹1,915.40 | 37.1 | 12.9% | 15.5% | 34.3% | +45.3% | 84 | BOUNCE FROM SUPPORT | +72.3% | +34.4% | +20.8% | +16.7% |
| GLAND | ₹3,061.80 | 44.7 | 16.8% | 21.3% | 9.6% | +63.8% | 83 | BREAKOUT | +47.1% | -13.6% | +19.6% | +3.3% |
Data from TradeAlone · Updated daily
